Peptide News Digest

#Anant-Vinjamoori

3 stories

Industry · View digest

Hims & Hers Health (NYSE: HIMS) Q2 2026 Earnings Preview for Monday August 10 After Market Close With Koyfin Consensus Estimates of $730.12 Million Revenue (+20% YoY), $47.26 Million EBITDA (+7% YoY), and $0.11 Adjusted Diluted EPS; Analyst Focus on the Peptide-Compounding Revenue Trajectory (Leerink Estimates $440 Million Peptide Sales in 2026 Representing Roughly 15% of the Projected 2026 Revenue Midpoint) and the Post-PCAC Investor Narrative Following the July 23-24 FDA Advisory Panel 6-of-7 Vote Recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List (DSIP Rejected)

Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close, with a live conference call scheduled for 5:00 PM ET. Koyfin consensus estimates: revenue of $730.12 million (+20% year-over-year), $47.26 million EBITDA (+7% YoY), and $0.11 adjusted diluted EPS. Analyst focus areas beyond the top-line numbers: the peptide-compounding revenue trajectory following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List (DSIP was rejected); the branded GLP-1 supply migration through the Novo Nordisk Wegovy/Ozempic and Eli Lilly Zepbound/Mounjaro commercial partnerships since Q1 2026; and management commentary on the FDA rulemaking timeline (typically 12-24 months per PCAC-recommended substance) that gates when the July 23-24 PCAC recommendation actually translates into new compounded-peptide revenue lines. Leerink analysts estimate Hims peptide sales at approximately $440 million in 2026, representing roughly 15% of the projected 2026 revenue midpoint; Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC public-comment testimony (which reportedly moved several undecided panelists on the harm-reduction argument for legal 503A compounded peptides) added a public-facing dimension to the Hims peptide strategy that will likely be referenced on the earnings call.

Industry · View digest

Hims & Hers Health (NYSE: HIMS) Shares Surge 10-13% Intraday Thursday July 23 Following the FDA PCAC Advisory Panel Vote in Favor of Adding BPC-157 and KPV to the 503A Compounding Pathway; Chief Medical Officer Dr. Anant Vinjamoori's Testimony Included the Anecdote That a Colleague Recently Sent Him a Photograph of a Bodega in Queens Selling Peptides, Arguing That a No Vote Would Push the Trade Deeper Into an Unregulated Gray Market With 'No Production or Sourcing Standards, No Physician, No Monitoring, and No Record'

Hims & Hers Health (NYSE: HIMS) shares surged 10-13% intraday on Thursday July 23, 2026 following the FDA Pharmacy Compounding Advisory Committee (PCAC) 8-6 votes in favor of adding BPC-157 and KPV to the Section 503A Bulks List. The stock reaction reflected investor recognition that Hims & Hers is one of the largest telehealth commercial channels positioned to sell legally compounded peptides through licensed 503A pharmacies if the FDA follows the advisory recommendation and completes rulemaking. Hims Chief Medical Officer Dr. Anant Vinjamoori's public-comment testimony was reportedly influential in the panel outcome. Vinjamoori shared the anecdote that a colleague had recently sent him a photograph of a bodega in Queens selling peptides, then argued: 'A no vote would not end those distribution channels or use. It would instead move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record.' Vinjamoori also acknowledged the 'relatively sparse clinical evidence for these peptides' before making the harm-reduction argument. Hims stands to benefit commercially: the company has built peptide capabilities including a California manufacturing facility acquired in 2025.

Regulatory · View digest

FDA Pharmacy Compounding Advisory Committee Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Tonight Wednesday July 22 With Approximately 1,860 Public Comments Filed on the Seven-Peptide Review (BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon); Hims Chief Medical Officer Dr. Anant Vinjamoori Confirmed Hims Will Testify at the Thursday July 23 Hearing and Publicly Acknowledged the 'Relatively Sparse Clinical Evidence for These Peptides' While Confirming Hims Plans to Offer the Peptides If the FDA Reclassifies Them

The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.